Weight-loss research by compound and evidence

Weight-management evidence ranges from large clinical trials to early animal experiments. Those findings should not receive a common label of proven fat loss. Body weight, visceral fat, appetite and metabolic markers are separate outcomes, and evidence applies to the formulation and population studied.

Read the treatment and comparator together

A clinical result should name the participants, treatment duration, comparator and relevant background care. Look for how the analysis handled people who stopped treatment, since discontinuation can change the apparent effect. Gastrointestinal symptoms, withdrawal rates and other harms belong beside weight-change results. A trial product cannot certify a research supplier's vial.

Distinguish weight loss from narrower endpoints

A change in visceral fat in a defined clinical population is not automatically evidence for general weight loss. A rise in adiponectin is a biomarker finding, not proof that administering adiponectin reduces weight. An animal experiment showing altered metabolism supplies a reason for further research without establishing human efficacy or a regimen.

Avoid treating mechanisms as rankings

Different mechanisms cannot be ranked by the strength of their marketing description. Compare controlled clinical outcomes when they are available and clearly label exploratory work when they are not. An approved product, an investigational trial material and a research chemical have different evidence and quality-control contexts.

Compare the actual research question

Examples of questions to ask when reading this research
Compound	Question	Evidence context
Tirzepatide	Is there a large clinical weight-management trial?	SURMOUNT-1 tested tirzepatide against placebo in adults with obesity or overweight and a weight-related complication, without diabetes, over 72 weeks. Its result concerns that clinical setting. Original study
Tesamorelin	Is visceral fat reduction the same as general weight loss?	The cited trial studied abdominal fat accumulation in people with HIV. Its main endpoint was CT-measured visceral fat, not a general obesity treatment outcome. Original study
Adiponectin	Was adiponectin the administered treatment?	The fish-oil study measured adiponectin in healthy dogs. It did not test administering adiponectin and found no significant change in their weight. Original study
SLU-PP-332	Do metabolic mouse findings establish clinical efficacy?	The cited experiments studied mouse models of obesity and metabolic syndrome. Human weight-management benefit needs separate evidence. Original study

Using the evidence

Compare evidence for the specific product and outcome. The individual profiles separate clinical trial findings, regulated product information and experimental mechanisms without presenting research-vial shopping as a treatment decision.

How to read studies and quantities · Research library

Research profiles in this topic

5-Amino-1MQ
5-Amino-1MQ belongs in a small-molecule research category, despite appearing in many peptide catalogs. Interest centers on inhibiting nicotinamide N-methyltransferase, or NNMT. The selected evidence supports studying that target in metabolism and muscle repair; it does not establish a consumer weight-loss or anti-aging treatment.
Adiponectin
Adiponectin is a protein hormone associated with fat tissue and metabolic signaling. Many papers measure its concentration while testing another intervention. That makes adiponectin an outcome or biomarker in those studies, not the treatment being given.
Adipotide
Adipotide is an experimental peptidomimetic designed to target blood vessels in white adipose tissue. Animal studies reported weight and fat reductions, but the same research raises kidney-safety concerns. These findings do not establish a human obesity treatment or a safe self-use regimen.
AOD-9604
AOD-9604 is a modified growth-hormone-derived peptide investigated in metabolic and cartilage research. Animal findings generated interest, but they do not establish human fat loss. FDA’s December 2024 assessment described a clinical obesity-development record that generally failed to show benefit over placebo.
Cagrilintide
Cagrilintide is a long-acting amylin analogue investigated for weight management. Unlike many compounds in peptide catalogs, it has randomized human outcome data. Those data still require careful attribution: cagrilintide alone and its combination with semaglutide are different interventions.
Chitosan
Chitosan is a polysaccharide derived from chitin, rather than a peptide. It appears both as an oral supplement and as a material used in drug-delivery research. Those roles should be separated before using a paper to support weight, liver or wound-related claims.
Follistatin 344
Follistatin is a protein involved in signaling by members of the TGF-beta family. “Follistatin 344” appears in experimental gene-transfer literature, but that does not mean an injectable product sold with the same number reproduces the intervention. The distinction between a gene construct, its processed protein and a short inhibitory fragment is central to evaluating muscle-growth claims.
GLP-1
GLP-1, or glucagon-like peptide-1, is a hormone name. It is also used informally to describe medicines that act at the GLP-1 receptor. Those uses should be separated: evidence for a named medicine and formulation is not evidence for a vial labeled only “GLP-1.”
HCG
Human chorionic gonadotropin, or hCG, is a hormone with established product-specific medical uses. It is not a generic recovery peptide or a validated weight-loss aid. An accurate overview separates a prescription medicine’s documented uses from claims attached to an unspecified laboratory product.
L-Carnitine
L-carnitine participates in fatty-acid metabolism. Small oral nutrition studies and licensed deficiency treatments answer different questions from injectable fat-loss claims.
MOTS-c
MOTS-c is a 16-residue mitochondrial-derived peptide studied in metabolism and exercise biology. Mouse administration and human exercise observations answer different questions.
Pramlintide
Pramlintide is an amylin analogue used with mealtime insulin in selected patients with diabetes. Its established use is different from experimental appetite or weight-loss claims.
SLU-PP-332
SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors. Mouse studies examine exercise-like metabolic responses; it is not a peptide or a proven exercise replacement.
Tesamorelin
Tesamorelin is a GHRH analogue approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management.
Tirzepatide
Tirzepatide has strong clinical evidence for specific diabetes and weight-related indications. Approval belongs to defined prescription products, not generic research vials.